Alpha Profiles · Company Profile

NEUROONE MEDICAL TECHNOLOGIES Corp

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/neuroone-medical-technologies-corp

Entity: Public listing published
Primary listing: NASDAQ: NMTC
Verification: Partially verified
Last reviewed: 2026-10-07T06:08:55.166756+00:00

Overview

Alpha's canonical identity and public leadership record for NEUROONE MEDICAL TECHNOLOGIES Corp.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

5 public records

Christopher Volker

Chief Operating Officer

State: confirmed
Effective: From Mar 9, 2026
Confidence: 94%
Evidence: NMTC DEF 14A executive officersMar 9, 2026

David Rosa

Chief Executive Officer, President and Director

State: confirmed
Effective: From Mar 9, 2026
Confidence: 94%
Evidence: NMTC DEF 14A executive officersMar 9, 2026

Emily Johns

Chief Administrative Officer, General Counsel

State: confirmed
Effective: From Mar 9, 2026
Confidence: 94%
Evidence: NMTC DEF 14A executive officersMar 9, 2026

Ronald McClurg

Chief Financial Officer

State: confirmed
Effective: From Mar 9, 2026
Confidence: 94%
Evidence: NMTC DEF 14A executive officersMar 9, 2026

Steve Mertens

Chief Technology Officer

State: confirmed
Effective: From Mar 9, 2026
Confidence: 94%
Evidence: NMTC DEF 14A executive officersMar 9, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 7, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

5 public records

David Rosa

Director

Not independent

State: confirmed
Effective: From Jan 1, 2017
Confidence: 85%
Evidence: NEUROONE MEDICAL TECHNOLOGIES Corp DEF 14A 2026-03-09Mar 9, 2026

Edward Andrle

Director

IndependentAuditNominating and Governance · Chair

State: confirmed
Effective: From Jan 1, 2020
Confidence: 85%
Evidence: NEUROONE MEDICAL TECHNOLOGIES Corp DEF 14A 2026-03-09Mar 9, 2026

Jason Mills

Director

IndependentCompensationNominating and Governance

State: confirmed
Effective: From Jan 1, 2025
Confidence: 85%
Evidence: NEUROONE MEDICAL TECHNOLOGIES Corp DEF 14A 2026-03-09Mar 9, 2026

Jeffrey S. Mathiesen

Director

IndependentAudit · ChairCompensationNominating and Governance

State: confirmed
Effective: From Jan 1, 2017
Confidence: 85%
Evidence: NEUROONE MEDICAL TECHNOLOGIES Corp DEF 14A 2026-03-09Mar 9, 2026

Paul Buckman

Director

IndependentAuditCompensation · Chair

State: confirmed
Effective: From Jan 1, 2017
Confidence: 85%
Evidence: NEUROONE MEDICAL TECHNOLOGIES Corp DEF 14A 2026-03-09Mar 9, 2026

Committees

3 public records

Membership and chair roles are projected from current board seats. A chair is shown only when a stored chair flag says so.

Audit

Chair: Jeffrey S. Mathiesen
Members: Jeffrey S. Mathiesen (Chair); Edward Andrle; Paul Buckman

Compensation

Chair: Paul Buckman
Members: Paul Buckman (Chair); Jason Mills; Jeffrey S. Mathiesen

Nominating and Governance

Chair: Edward Andrle
Members: Edward Andrle (Chair); Jason Mills; Jeffrey S. Mathiesen

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-07T06:08:55.166756+00:00